Rapid Development of Vaccines and Deployment of Antiviral Therapies To Prevent & Heal Coronavirus

[Intercessor]

I prayed for this in Jesus Name. Amen.

OCALA, FL ACCESSWIRE May 14, 2020 AIM ImmunoTech (AIM) today announced that the U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of the Company's lead asset, Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus. The Company also provided a corporate business update and reported financial results for the first quarter ended March 31, 2020.
The new clinical trial, to be conducted at Roswell Park Comprehensive Cancer Center under the leadership of Pawel Kalinski, MD, PhD, a pioneer in developing this combination as an investigational treatment for cancer, and Brahm Segal, MD, will test the safety of this combination regimen in patients with cancer and mild to moderate COVID-19, and the extent to which this therapy will promote clearance of the SARS-CoV-2 virus from the upper airway. The phase 1/2b study will enroll approximately 40 patients in two stages. Phase 1 will see 12-24 patients receiving both Ampligen and interferon alfa-2b at escalating doses. Once that initial phase is complete, further study participants will be randomized to two arms: one receiving the two-drug combination and a control group who will not receive Ampligen or interferon alfa but will receive best available care. AIM ImmunoTech intends to be a financial sponsor of the study and will provide Ampligen (rintatolimod) at no charge for this study. Additional information on the clinical trial is available at clinicaltrials.gov.

 

[Intercessor]

God will protect you in your time of need. I pray that your prayer will be answered soon.
"For our light and momentary troubles are achieving for us an eternal glory that far outweighs them all." 2 Corinthians 4:17
May the Lord wrap his arms around you and keep you at peace. God Bless you with our Father always at your side protecting you and your needs.

OCALA, FL ACCESSWIRE May 14, 2020 AIM ImmunoTech (AIM) today announced that the U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of the Company's lead asset, Ampligen (rintatolimod), in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus. The Company also provided a corporate business update and reported financial results for the first quarter ended March 31, 2020.
The new clinical trial, to be conducted at Roswell Park Comprehensive Cancer Center under the leadership of Pawel Kalinski, MD, PhD, a pioneer in developing this combination as an investigational treatment for cancer, and Brahm Segal, MD, will test the safety of this combination regimen in patients with cancer and mild to moderate COVID-19, and the extent to which this therapy will promote clearance of the SARS-CoV-2 virus from the upper airway. The phase 1/2b study will enroll approximately 40 patients in two stages. Phase 1 will see 12-24 patients receiving both Ampligen and interferon alfa-2b at escalating doses. Once that initial phase is complete, further study participants will be randomized to two arms: one receiving the two-drug combination and a control group who will not receive Ampligen or interferon alfa but will receive best available care. AIM ImmunoTech intends to be a financial sponsor of the study and will provide Ampligen (rintatolimod) at no charge for this study. Additional information on the clinical trial is available at clinicaltrials.gov.